Patents
US 12139709 B2: Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
- Granted
- 2024-11-12
- Filed
- 2021-06-09 application 17343447
- Type
- Utility · 16 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
The present disclosure relates to modified antisense oligonucleotides. The nucleotides described herein are of 10 to 40 nucleobases and include a targeting sequence complementary to a target region within intron 1 of a pre-mRNA of the human alpha glucosidase (GAA) gene. The target region includes at least one additional nucleobase compared to the targeting sequence, wherein the at least one additional nucleobase has no complementary nucleobase in the targeting sequence, and wherein the at least one additional nucleobase is internal to the target region.
Source: PVGPATDIS, file of 2026-04-10 (ipg241112.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| SAREPTA THERAPEUTICS, INC. 126 patents | US company or organization | Cambridge, MA | Sarepta Therapeutics, Inc. Form D issuer EXACT high confidence: identical full name and state SAREPTA THERAPEUTICS, INC. SEC filer EXACT medium confidence: identical full name, one of each nationally | PVGPATDIS, file of 2026-04-10 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| Frederick Joseph SCHNELL | Cambridge, MA | 10 | PVGPATDIS, file of 2026-04-10 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| C12N | Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media | C12N15/113 | PVGPATDIS, file of 2026-04-10 |
| A61K | Preparations for medical, dental or toiletry purposes | A61K9/0019 | PVGPATDIS, file of 2026-04-10 |
| A61P | Specific therapeutic activity of chemical compounds or medicinal preparations | A61P3/00 | PVGPATDIS, file of 2026-04-10 |
| C07H | Sugars; derivatives thereof; nucleosides; nucleotides; nucleic acids | C07H21/02 | PVGPATDIS, file of 2026-04-10 |
| C12Y | Enzymes | C12Y302/0102 | PVGPATDIS, file of 2026-04-10 |
| Y02P | Climate change mitigation technologies in the production or processing of goods | Y02P20/582 | PVGPATDIS, file of 2026-04-10 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
| Recorded | What | From | To | Reel/frame | Source |
|---|---|---|---|---|---|
| 2025-05-07 | Security interest Security interest Security interest | SAREPTA THERAPEUTICS, INC. signed 2025-02-13 | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT CHICAGO, IL | 71218/445 | PASDL, file of 2026-10-15 |
Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.